There are many trials and tribulations facing new drug approvals for men with prostate cancer. This is particularly true for men the drugs that are designed to fight metastatic castration-resistant prostate cancer (mCRPC) because of the many new treatments, all with life extending ability, that we now have available to use. The good news is [...]
I stumbled upon a fascinating piece of research from Iceland that looked at the role of Circadian Disruption in Prostate Cancer Development. Knowing my own very poor sleeping patterns and having heard many other men with advanced prostate cancer complaining about very similar experiences it peaked my interest. The researchers pointed out that there have [...]
It is commonly known that our current clinical trials struggle to enroll adequate numbers of minority men. Our inability to enroll a cross section of men that truly reflects the general population in prostate cancer clinical trials means that our results might not accurately reflect the best information for a minority man. The lack of [...]
Approximately 2 years ago Malecare and the New York State Prostate Coalition began asking questions about where the State of New York was hiding approximately $3,000,000 in funding for prostate cancer research. Each year New York State residents are asked to check off a little box on their state tax return donating an additional dollar [...]
Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often [...]
We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being [...]
I have been relatively quiet about the skyrocketing cost of drugs, but it has now become impossible to remain out of the fray. A Pharmaceutical company recently acquired a drug called Daraprim, the drug treats potentially fatal parasitic infections. After its acquisition the company raised the price of Daraprim by almost 5,0000%. When confronted with [...]
As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough [...]
Because of the large amount of prostate cancer screening there has been a major shift in initial staging in prostate cancer in western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to currently less than 10%. Despite this very significant drop in late stage diagnoses prostate cancer is [...]
There have been some randomized studies that have shown that when prednisone is used in combination with docetaxel (chemotherapy) there is an improved survival in men who have metastatic castration-resistant prostate cancer (mCRPC). To add to our understanding of the possible clinical value of this combination of drugs some researchers have retrospectively evaluated whether the [...]
